200 related articles for article (PubMed ID: 28075446)
1. NF‑κB inhibition is associated with OPN/MMP‑9 downregulation in cutaneous melanoma.
Guarneri C; Bevelacqua V; Polesel J; Falzone L; Cannavò PS; Spandidos DA; Malaponte G; Libra M
Oncol Rep; 2017 Feb; 37(2):737-746. PubMed ID: 28075446
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial.
Prasmickaite L; Berge G; Bettum IJ; Aamdal S; Hansson J; Bastholt L; Øijordsbakken M; Boye K; Mælandsmo GM
Cancer Immunol Immunother; 2015 Jun; 64(6):769-76. PubMed ID: 25832001
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
Das R; Philip S; Mahabeleshwar GH; Bulbule A; Kundu GC
IUBMB Life; 2005 Jun; 57(6):441-7. PubMed ID: 16012053
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment in diffuse large B-cell lymphoma: Matrixmetalloproteinases activation is mediated by osteopontin overexpression.
Malaponte G; Hafsi S; Polesel J; Castellano G; Spessotto P; Guarneri C; Canevari S; Signorelli SS; McCubrey JA; Libra M
Biochim Biophys Acta; 2016 Mar; 1863(3):483-489. PubMed ID: 26381542
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin expression in plasma of melanoma patients and in melanocytic tumours.
Maier T; Laubender RP; Sturm RA; Klingenstein A; Korting HC; Ruzicka T; Berking C
J Eur Acad Dermatol Venereol; 2012 Sep; 26(9):1084-91. PubMed ID: 21838826
[TBL] [Abstract][Full Text] [Related]
6. OPG, OPN, EGF and VEGF Levels at Individual Breslow Score Stages in Malignant Melanoma.
Treskova I; Topolcan O; Windrichova J; Simanek V; Slouka D; Treska V; Kucera R
Anticancer Res; 2018 Aug; 38(8):4907-4911. PubMed ID: 30061268
[TBL] [Abstract][Full Text] [Related]
7. An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells.
Lai CF; Seshadri V; Huang K; Shao JS; Cai J; Vattikuti R; Schumacher A; Loewy AP; Denhardt DT; Rittling SR; Towler DA
Circ Res; 2006 Jun; 98(12):1479-89. PubMed ID: 16709900
[TBL] [Abstract][Full Text] [Related]
8. Clinical Significance of Circulating Osteopontin Levels in Patients With Lung Cancer and Correlation With VEGF and MMP-9.
Kerenidi T; Kazakou AP; Lada M; Tsilioni I; Daniil Z; Gourgoulianis KI
Cancer Invest; 2016 Sep; 34(8):385-92. PubMed ID: 27624849
[TBL] [Abstract][Full Text] [Related]
9. Elevated microRNA‑145‑5p increases matrix metalloproteinase‑9 by activating the nuclear factor‑κB pathway in rheumatoid arthritis.
Wang X; Tang K; Wang Y; Chen Y; Yang M; Gu C; Wang J; Wang Y; Yuan Y
Mol Med Rep; 2019 Sep; 20(3):2703-2711. PubMed ID: 31322192
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin.
Kale S; Raja R; Thorat D; Soundararajan G; Patil TV; Kundu GC
Oncogene; 2014 May; 33(18):2295-306. PubMed ID: 23728342
[TBL] [Abstract][Full Text] [Related]
11. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin stimulates melanoma growth and lung metastasis through NIK/MEKK1-dependent MMP-9 activation pathways.
Rangaswami H; Kundu GC
Oncol Rep; 2007 Oct; 18(4):909-15. PubMed ID: 17786354
[TBL] [Abstract][Full Text] [Related]
13. Serum markers to detect metastatic uveal melanoma.
Barak V; Frenkel S; Kalickman I; Maniotis AJ; Folberg R; Pe'er J
Anticancer Res; 2007; 27(4A):1897-900. PubMed ID: 17649791
[TBL] [Abstract][Full Text] [Related]
14. MMP, VEGF and TIMP as prognostic factors in recurring bladder cancer.
Wieczorek E; Jablonowski Z; Tomasik B; Konecki T; Jablonska E; Gromadzinska J; Fendler W; Sosnowski M; Wasowicz W; Reszka E
Clin Biochem; 2015 Dec; 48(18):1235-40. PubMed ID: 26197083
[TBL] [Abstract][Full Text] [Related]
15. Clinical and
Wong JPC; Wei R; Lyu P; Tong OLH; Zhang SD; Wen Q; Yuen HF; El-Tanani M; Kwok HF
Int J Biol Sci; 2017; 13(11):1373-1386. PubMed ID: 29209142
[TBL] [Abstract][Full Text] [Related]
16. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
Larsen AC
Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
[TBL] [Abstract][Full Text] [Related]
17. Modification of osteopontin and MMP-9 levels in patients with psoriasis on anti-TNF-α therapy.
Buommino E; De Filippis A; Gaudiello F; Balato A; Balato N; Tufano MA; Ayala F
Arch Dermatol Res; 2012 Aug; 304(6):481-5. PubMed ID: 22684781
[TBL] [Abstract][Full Text] [Related]
18. Plasma osteopontin concentrations in patients with cutaneous melanoma.
Filia A; Elliott F; Wind T; Field S; Davies J; Kukalizch K; Randerson-Moor J; Harland M; Bishop DT; Banks RE; Newton-Bishop JA
Oncol Rep; 2013 Oct; 30(4):1575-80. PubMed ID: 23934016
[TBL] [Abstract][Full Text] [Related]
19. Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis.
Zheng W; Li R; Pan H; He D; Xu R; Guo TB; Guo Y; Zhang JZ
Arthritis Rheum; 2009 Jul; 60(7):1957-65. PubMed ID: 19565503
[TBL] [Abstract][Full Text] [Related]
20. Recombinant osteopontin attenuates hyperoxia-induced acute lung injury through inhibiting nuclear factor kappa B and matrix metalloproteinases 2 and 9.
Zhang X; Liu F; Zhu G; Wang Z
Chin Med J (Engl); 2014; 127(23):4025-30. PubMed ID: 25430443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
